排名前五的靶点	数量

ALK5(转化生长因子β受体1)	1
JAK1(酪氨酸蛋白激酶JAK1)	1
BAP1(BRCA1 associated protein 1)	1
Akt x SOX2	1
S1P(membrane bound transcription factor peptidase, site 1)	1

关联

项与 Ewha Womans University 相关的药物

Sincalide

辛卡利特

靶点

CCKA x CCKB

作用机制

CCKA激动剂 [+1]

在研机构

Maia Pharmaceuticals, Inc. [+3]

原研机构

Bracco International BV

在研适应症

胆囊疾病 [+4]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1976-07-21

Isuzinaxib

靶点

NOX

作用机制

NOX抑制剂

在研机构

Ewha Womans University [+1]

原研机构

Ewha Womans University

在研适应症

糖尿病肾病 [+1]

非在研适应症

新型冠状病毒感染 [+1]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

TRAP1 inhibitors(Ewha Womans University)

靶点

TRAP1

作用机制

TRAP1拮抗剂

在研机构

Ewha Womans University

原研机构

Ewha Womans University

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

177

项与 Ewha Womans University 相关的临床试验

NCT07241143

/ Not yet recruitingN/AIIT

Comparison of the Efficacy and Safety of Extra-Peritoneal Tunneling Drain Fixation Versus Conventional Drain Insertion Following Anterior or Low Anterior Resection (ExPeTuD Trial): A Multi-Center Randomized Controlled Trial

The goal of this clinical trial is to learn whether the extra-peritoneal tunneling (EPT) drain fixation method works better and more safely than the conventional drain insertion method after rectal cancer surgery.
It will also learn about the safety and possible complications of the EPT technique.
The main questions it aims to answer are:
Does the EPT drain fixation method increase the success rate of conservative management (drain maintenance and/or antibiotics) when an anastomotic leak occurs?
Does the EPT method reduce the rate of drain displacement compared with the conventional method?
Are there any safety concerns or complications associated with the EPT method?
Researchers will compare EPT drain fixation to the conventional drain method to see which approach provides better outcomes after anterior or low anterior resection for rectal cancer.
Participants will:
Undergo anterior or low anterior resection for rectal cancer as part of their standard surgical treatment.
Be randomly assigned to either the EPT drain fixation group or the conventional drain group.
Receive the same postoperative care as usual, including follow-up imaging to monitor drain position and recovery.
Be observed for postoperative outcomes such as anastomotic leakage, drain position, and related complications until recovery.
This study will help determine whether securing the drain through an extra-peritoneal tunnel can prevent drain movement, improve early management of leakage, and enhance patient recovery after rectal surgery.

开始日期2025-12-01

申办/合作机构

Yeungnam University

[+13]

KCT0011160

/ RecruitingN/AIIT

ICT-Based Multidomain Health and Cognitive Function Assessment in Older Adults with Diabetes at High-Risk of Cognitive Impairment

开始日期2025-09-17

申办/合作机构

Ewha Womans University

KCT0010942

/ Not yet recruitingN/AIIT

Feasibility and Performance Evaluation of a New Implant System in Patients Receiving Antiresorptive or Antiangiogenic Therapy: A Single-Arm Prospective Clinical Trial with 30 Patients

开始日期2025-08-29

申办/合作机构

Ewha Womans University

100 项与 Ewha Womans University 相关的临床结果

登录后查看更多信息

0 项与 Ewha Womans University 相关的专利（医药）

登录后查看更多信息

13,411

项与 Ewha Womans University 相关的文献（医药）

2026-12-01·Nano-Micro Letters

Chirality-Induced Suppression of Singlet Oxygen in Lithium–Oxygen Batteries with Extended Cycle Life

Article

作者: Jang, Dohyub ; Kim, Youngsin ; Kim, Dong Ha ; Chae, Kyunghee ; Oh, Yookyeong ; Kim, Hyuk-Joon ; Moon, Jooho ; Kang, Kisuk ; Son, Jaehyun ; Marques Mota, Filipe ; Han, Jeong Woo ; Kim, Youngbi ; Lee, Hyun Jeong ; Hahn, Hosik

Abstract:

Lithium–oxygen (Li–O2) batteries are perceived as a promising breakthrough in sustainable electrochemical energy storage, utilizing ambient air as an energy source, eliminating the need for costly cathode materials, and offering the highest theoretical energy density (~ 3.5 kWh kg–1) among discussed candidates. Contributing to the poor cycle life of currently reported Li–O2 cells is singlet oxygen (1O2) formation, inducing parasitic reactions, degrading key components, and severely deteriorating cell performance. Here, we harness the chirality-induced spin selectivity effect of chiral cobalt oxide nanosheets (Co3O4 NSs) as cathode materials to suppress 1O2 in Li–O2 batteries for the first time. Operando photoluminescence spectroscopy reveals a 3.7-fold and 3.23-fold reduction in 1O2 during discharge and charge, respectively, compared to conventional carbon paper-based cells, consistent with differential electrochemical mass spectrometry results, which indicate a near-theoretical charge-to-O2 ratio (2.04 e−/O2). Density functional theory calculations demonstrate that chirality induces a peak shift near the Fermi level, enhancing Co 3d–O 2p hybridization, stabilizing reaction intermediates, and lowering activation barriers for Li2O2 formation and decomposition. These findings establish a new strategy for improving the stability and energy efficiency of sustainable Li–O2 batteries, abridging the current gap to commercialization.

2026-03-01·BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of novel imidazo[4,5-b]pyridine derivatives as noncovalent reversible Bruton’s tyrosine kinase inhibitors

Article

作者: Lee, Danbi ; Hwang, Inah ; Kim, Yeojeong ; Lee, Kyoungyim ; Park, Bomi ; Lee, Yeji ; Kim, Soobin ; Sun, Jingyang ; Ryu, Jae-Sang

Bruton's tyrosine kinase (BTK) has emerged as a validated therapeutic target for B-cell malignancies and autoimmune disorders, and covalent BTK inhibitors have demonstrated remarkable clinical efficacy. However, because of concerns regarding their off-target effects and safety profiles, there is research interest in developing noncovalent, reversible inhibitors. Herein, we report the design, synthesis, and biochemical evaluation of novel imidazo[4,5-b]pyridine derivatives as noncovalent BTK inhibitors. Through a concise three-step synthetic route, we prepared 16 structurally diverse analogs (6a-p) bearing various substituents on the imidazole scaffold. The results of biochemical evaluation showed that 6b, 6o, and 6p are the most potent inhibitors, with IC₅₀ values of 1.14, 1.54, and 2.46 μM, respectively. The results of structure-activity relationship studies revealed that 2,4-dihydroxyphenyl substitution on the A-ring and extended functionalities (morpholinomethyl or 4-acetamido group) on the B-ring significantly enhanced the inhibition of BTK. The results of molecular docking studies elucidated key binding interactions and showed that the hydroxyl groups form hydrogen bonds with the Thr474 gatekeeper residue and the Met477 hinge region residue, whereas B-ring substituents extend toward the DFG motif. The preliminary kinase selectivity profiling of 6b against 39 kinases demonstrated promising selectivity, with significant inhibition observed primarily for BTK and c-Src. Although these compounds show moderate potency compared with clinically approved BTK inhibitors, their noncovalent, reversible nature offers potential advantages with regard to selectivity, toxicity, and pharmacological effects. Moreover, these compounds represent valuable starting points for further optimization toward developing novel therapeutics for B-cell malignancies and autoimmune disorders with potentially improved safety profiles for long-term treatment.

2026-03-01·TOXICOLOGY IN VITRO

Development of an in vitro acute respiratory toxicity test using the SoluAirway™, 3D human airway model

Article

作者: Kim, Ga-Eun ; Lee, Su-Hyun ; Choe, Ji-Woo ; Lee, Geon-Hee ; Kim, Ha-Ryong ; Lim, Kyung-Min

This study presents a novel in vitro method for acute respiratory toxicity testing using the SoluAirway™ model (SoluAirway™ ARTT). SoluAirway™ is a 3D human airway tissue model constructed from primary human nasal epithelial cells, recapitulating the structural and molecular characteristics of the human bronchial epithelium. Tissues were exposed to four concentrations of test chemicals using two application methods-vapor-cap and direct application-for 4 h, followed by a 20 h post-incubation. Tissue viability was assessed using the MTT assay. Following established classification approaches, EC₅₀ and EC₂₅ values were determined and used to assign GHS acute inhalation toxicity categories: EC₂₅/₅₀ ≤ 5 mg/tissue: GHS Category 1 or 2, 5 < EC₂₅/₅₀ ≤ 25 mg/tissue: GHS Category 3 or 4 and EC₂₅/₅₀ > 25 mg/tissue: No Category. The direct application method showed an excellent predictive accuracy of 76.92 % (10/13). When 20 additional reference chemicals (33 total) were tested, the EC₅₀-based classification achieved a predictive accuracy of 75.76 % (25/33). Notably, applying a fixed-dose viability threshold (≤50 % viability at 5 mg/tissue for GHS 1/2; >50 % at 5 and ≤ 50 % at 25 mg/tissue for GHS 3/4; others as No Category) yielded comparable predictive performance. Collectively, these results suggest that SoluAirway™ ARTT is a promising, cost-effective alternative method for assessing acute inhalation toxicity.

项与 Ewha Womans University 相关的新闻（医药）

2025-10-26

·韩出国留学韩语辅导

韩国留学热门专业解析| 找到适合你的发展方向

韩国留学专业全解读热门专业与就业趋势韩国高等教育资源丰富、专业选择多元，本篇突破性梳理留学热门专业，为你定位未来发展方向，助力职业规划步步为营。韩国留学热门专业解析：找到适合你的发展方向在留学规划中，专业选择至关重要。韩国作为亚洲教育强国，凭借优质高等教育资源和邻近的地理位置，成为中国学生留学的热门之选。下面为大家解析韩国留学的热门专业，助你做出合适选择。信息技术与人工智能：数字化时代的中流砥柱韩国在半导体、通信技术和人工智能领域处于全球领先。三星、LG等知名企业与高校深度合作，推动技术创新。推荐专业计算机科学：该专业侧重算法设计和系统开发。首尔大学、KAIST（韩国科学技术院）的相关课程包含量子计算、区块链等前沿内容。数据科学与人工智能：延世大学与SK集团携手开设“AI + 医疗”跨学科项目。该专业毕业生大多能进入Naver、Kakao等科技行业领军企业。就业优势据韩国雇佣劳动部2023年数据，IT工程师平均年薪达7500万韩元（约合人民币40万元），远超其他行业。国内互联网大厂（如字节跳动、腾讯）对韩语 + 技术的复合型人才需求大，起薪普遍高于国内同专业毕业生。金融与商科管理：全球化商业精英的孵化地韩国金融业开放程度高，首尔江南区聚集了高盛、摩根士丹利等国际投行分支机构。推荐方向金融工程：成均馆大学GSB学院开设“金融科技与量化分析”课程，并与三星证券联合培养专业人才。国际商务：庆熙大学的Global MBA项目全英文授课，学生有机会参与现代、起亚等企业的海外市场拓展实战活动。院校特色延世大学管理学院（Yonsei SOM）获得AACSB认证，其毕业生在韩国四大会计师事务所的入职率超过60%。商科专业涵盖市场营销、国际商务、金融分析等方向，毕业生可进入跨国企业、银行、咨询公司等领域。韩资企业（如现代汽车、LG化学）在华分公司优先招聘懂韩语、熟悉韩国商业文化的毕业生，薪资较国内同类岗位高15% - 20%。文化创意产业：韩流文化背后的学术力量从K - POP到奈飞定制剧，韩国文化全球传播离不开高校对创意人才的培养。细分领域影视制作：中央大学戏剧电影系有独立制片厂，学生可参与CJ ENM（《寄生虫》制片方）的合作项目。游戏设计：世宗大学开设“元宇宙内容开发”专业，课程涉及Unity引擎编程和用户体验设计等。时尚营销：弘益大学与三星时尚研究所联合成立“智能纺织品设计”实验室，重点研究可穿戴设备和环保材料。语言要求多数专业要求TOPIK 5级，但东国大学的“全球文化内容”硕士项目提供英语授课选项。国内互联网平台（如抖音、B站）加速布局“国际化内容”，需大量熟悉韩流生产逻辑的人才，负责韩国区内容策划、创作者孵化等岗位。设计专业：创意与实用的完美融合韩国在游戏、动漫、服装等设计领域国际领先，艺术类院校在艺术设计方面优势明显。专业课程注重培养学生创意能力和实践技能，提供丰富实践机会和专业指导。推荐院校弘益大学、中央大学、建国大学、梨花女子大学。国内服装品牌（如李宁、波司登）加速国际化，需大量熟悉韩国潮流趋势的设计师，负责联名款开发、海外旗舰店设计等。机械工程与自动化：高端制造的核心支撑韩国在汽车工程、机器人、航空航天等领域技术深厚，现代汽车、起亚汽车等企业全球销量领先。机械专业涵盖智能制造、工业设计、新能源技术等方向，毕业生可进入汽车制造、装备研发、新能源等领域。就业优势国内新能源汽车产业爆发式增长，比亚迪、蔚来等企业急需具备韩国现代汽车技术背景的工程师，负责电池管理系统、智能驾驶辅助等核心模块研发。生命科学与医学：产学研融合的典范韩国政府计划2025年前投入2.5万亿韩元支持生物医药研发，高校研究成果能直接对接产业需求。前沿方向基因编辑与细胞治疗：首尔大学医学院与三星医疗中心合作开展CAR - T细胞临床试验。数字健康管理：高丽大学的“智能医疗系统工程”专业整合了AI诊断和远程医疗技术。专业选择建议结合个人兴趣与职业规划韩国高等教育体系课程设置注重实践导向与跨学科融合，选择专业时要兼顾个人兴趣、职业规划及院校优势学科。关注行业发展趋势 2025年韩国政府推出“数字新政2.0”，重点扶持人工智能、半导体、生物健康等领域，留学生可优先申请相关奖学金及就业支持项目。韩国留学不仅是学术深造，更是融入全球产业链的契机。从首尔大学的精密工程到中央大学的影视制作，每个专业都蕴含改变行业的潜力。希望本文能助你找到最适合的发展方向，开启成功留学之旅。北京韩语培训这里经营韩国留学业务和一对一线上、线下韩语培训。无论你身处全国哪个地区，都能在这里办理去韩留学相关事宜。对于想要利用寒假暑假集中提升韩语水平的同学，这里还开设了集训班。如果你也怀揣着韩国留学的梦想，渴望提升自己的韩语水平，那么不要犹豫了，快来报名吧！ END #韩国留学攻略 #韩语培训 #韩语培训机构# #韩语TOPIK考试 #韩语集训 #韩国留学专业

AACR会议引进/卖出

2025-07-22

·美通社

精准医学时代将重塑治疗方案、带动1.45万亿元产业投资并改变生命轨迹

上海 2025年7月22日 /美通社/ -- 一份集成业内权威专家见解的最新报告指出，亚太地区正迎来精准医学时代，一场突破性创新疗法的变革浪潮将重塑治疗方案、吸引资本涌入，并为患者带来福祉。中国有望从这股创新浪潮中显著受益，这些创新疗法为攻克并潜在治愈目前的"不治之症"带来了前所未有的希望。今日发布的《迎接治愈的曙光》白皮书深入分析了亚太地区精准医学的市场接纳程度。在这个变革的时代，传统的"千人一方"标准化处方正逐渐被个体化治愈疗法，即精准医学所取代。精准医学时代将成为中国医疗发展的重要转折点——创新疗法将带动产业投资热潮、促进民生并提升就业水平、带来更好的患者获益和医疗体系升级。L.E.K.咨询联合由16位亚太地区专家组成的咨询委员会开展的这项新研究显示，未来十年，精准医学预计将累计创造以下核心效益 [i] ：为中国制药价值链带来约1.45万亿元人民币（2,000亿美元）的直接经济投资在中国制药价值链创造多达14.2万个高技能工作岗位，并在诊断和医疗系统中创造额外就业机会通过对相关产业的带动作用产生乘数效应，并创造多达8.7万亿元人民币（1.2万亿美元）更广泛的间接经济效益目标患者寿命累计延长920万年减少2160亿元人民币（300亿美元）的医疗支出，缓解中国医疗资源和人力压力带动高达100亿至140亿元人民币（14亿至19亿美元）规模的临床试验活动，促进中国医疗可及性与医护人员发展 L.E.K.咨询全球医疗业务联合负责人、大中华区主管合伙人陈玮指出："约4000种细胞与基因疗法形成的临界规模正推动精准医学时代的到来。对中国患者和医疗机构而言，这是释放变革潜力的历史性机遇。具体而言，通过减少住院、用药、专科就诊和随访需求，延长患者高质量生存期，由此节省的医疗支出相当于1500万人的年均医疗总费用。" 精准医学带来治愈的曙光《迎接治愈的曙光》研究基于公开数据，分析了细胞疗法、基因疗法、靶向抗体疗法和药械联合疗法这四种新型技术的逾千项临床试验数据。上述技术之所以被归入"精准医学时代"的范畴是因为其具有三大特征：通过个性化治疗方案提升患者的健康获益，颠覆传统医疗模式，并且成为当前全球研发与产业投资的重点布局方向。尤为关键的是，专家认为某些既往的"不治之症 "——包括亚太地区高发的癌症和遗传病——可能即将迎来治愈的曙光。对外经济贸易大学于保荣教授表示：" 2022年中国新发癌症病例超480万，死亡病例逾250万。在罕见病领域，我国面临严峻诊断挑战，58%患者遭遇过误诊 [ii] 。精准疗法正在为这些重大医疗难题提供解决方案，有望成为中国应对关键疾病负担的新标准。" 精准医学发展面临哪些阻碍？精准医学时代正在深刻改变我们应对疾病的方式和患者治疗模式，这也对监管者与政策制定者提出了更高要求。要想充分释放这一时代的潜力，中国仍需在法规体系、专业认知及基础设施建设等方面不断完善和提升。为确保精准医学时代的潜能得到充分释放，本白皮书概述了三项重要政策建议：营造促进创新的支持环境完善精准医学的基础设施重视精准医学的相关教育完善监管审批框架、健全精准医学的定价、医保报销、筹资等制度机制。例如完善国家医保药品目录谈判机制，将公平性、疾病严重程度、生活质量改善、预期寿命延长及药品成本等多重因素纳入考量。提供战略性激励措施，促进对基因库、生物样本库、癌症数据库、大型人群队列资源和人工智能数据分析平台等重要精准医学基础设施的投资。制定临床指南，并为医患提供进一步教育，支持患者倡导组织的成立与发展。蔻德罕见病中心(CORD)创始人暨白皮书专家咨询委员会成员黄如方强调："精准医学新时代将为中国医疗体系转型提供强大助力。但这同时也意味着，包括医疗专业人士、产业领袖在内的所有利益相关方必须通力合作，才能确保患者真正受益于这些创新疗法。" 《迎接治愈的曙光》亚太系列白皮书包含四份区域市场报告，分别评估澳大利亚、中国、日本和韩国在精准医学应用中的障碍，提出改进建议，并测算大规模应用带来的经济社会价值。编者注：《迎接治愈的曙光》白皮书系列及顾问咨询委员会成员本系列白皮书由16位亚太地区权威专家组成的顾问咨询委员会提供学术支持，成员涵盖精准医学、卫生经济政策及患者体验等领域，并由强生公司赞助支持。委员会专家及具有亲身经历的潜在患者可接受访谈，就精准医学时代发展趋势、疗法价值及白皮书内容进行深度解读。澳大利亚中国韩国日本 Omico首席科学官 David Thomas MTP Connect董事会主席 Jaala Pulford 澳洲罕见癌症协会首席执行官Christine Cockburn 对外经济贸易大学教授及市场准入关键意见领袖于保荣教授 Guardant Health中国区负责人莫俊业蔻德罕见病中心 (CORD) 创始人, 中心主任黄如方同济大学医学院教授及肺癌领域关键意见领袖周彩存教授吉利德科学公司（韩国）前总经理 Paul Lee 首尔大学医院基因组医学部及罕见病中心罕见疾病治疗倡导者 Jin-Ah Kim 梨花女子大学健康融合系教授 Jeonghoon Ahn 兵库县立大学社会科学研究科特任教授，一般社团法人未来研究所卧龙代表理事 Teruyuki Katori 藤田医科大学教授Daisuke Sato 京都大学大学院医学研究科教授 Manabu Muto 京都大学医学部附属病院教授Masahiro Miyake Cancer Solutions创始人兼首席执行官 Naomi Sakurai 肺癌HER2"HER HER"项目负责人 Keisuke Shimizu [i] L.E.K Consulting. On the Cusp of a Cure 2025. [ii] Zhang S.,2019. Diagnosis and treatment of rare diseases in China . Clinical Focus, 34(3), 197-200. Available at: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2019.03.001 关于<\/b> L.E.K.<\/b> 咨<\/b> 询<\/b> L.E.K.咨询是一家全球性的战略咨询公司，致力于帮助业务领导者把握竞争优势，获取持续增长。L.E.K.的深刻洞见帮助客户重塑业务发展轨迹，发掘机遇，并为其赋能，以把握每一个关键时刻。自1983年创立以来，L.E.K.团队遍布全球，跨越美洲、欧洲、中东和亚太地区，与来自各个行业的跨国企业、创业企业以及私募股权投资者展开合作，为其提供战略咨询服务。如欲了解更多信息，请访问 lek.com。 L.E.K. Consulting是L.E.K. Consulting LLC的注册商标。本文档中提及的所有其他产品和品牌均为其各自所有者的财产。 © 2025 L.E.K. Consulting<\/p>

2025-05-19

·Healthcare IT News

Korea launches $7M big data project to boost autism screening

A consortium led by South Korea's top universities, Yonsei University and Seoul National University, will embark on a national project promoting the early detection of autism spectrum disorder in the country. Backed by the National Center for Mental Health and the Ministry of Health and Welfare, the project received 9.2 billion won ($6.6 million) in government funding. According to a media release, the project aims to develop AI-powered digital and medical devices for screening autism, which are targeted for release by 2028. The devices will be run by algorithms based on data from a cohort of 1,200 infants and toddlers below 48 months. Additionally, applications for an innovative medical device designation from the Ministry of Food and Drug Safety will be pursued. WHY IT MATTERS A recent article noted an overall increase in cases of ASD among Korean children and adolescents from 2011 to 2021. It has been estimated that the prevalence of DSM-5-defined ASD is at 2.20% . This trend may necessitate calibrating strategies to enable timelier and more effective prevention and care of children with autism. However, current approaches in ASD diagnosis, according to the Yonsei-SNU-led consortium, are largely dependent on specialists' findings and subjective observations of guardians, which often render them inconsistent and short of objectivity. "The AI-based [ASD] screening assistive medical device to be developed through this project will be an opportunity to shift the paradigm of early autism diagnosis and treatment," explained Chun Geun-ah, professor at Yonsei University Severance Hospital and principal project investigator. "The consortium will establish a foundation to overcome the limitations of diagnosing [ASD] and lead to better treatment outcomes," Kim Boong-nyeon, SNU Hospital (SNUH) professor and co-principal investigator, also said. The consortium involves several major hospitals, such as Yonsei's Gangnam Severance Hospital, Ewha Womans University Hospital in Seoul and Mokdong, and Seoul St. Mary’s Hospital, and digital health companies, including HurayPositive and Adotcure. THE LARGER TREND In 2023, SNUH opened a living laboratory to collect data that will be used to develop algorithm-driven models for detecting and personalising the treatment of ASD. The lab, also supported by the NCMH, serves as a bedrock for new digital therapeutics and the discovery of autism biomarkers. AI has seen increasing applications in ASD screening and treatment. EarliTec Diagnostics in the United States is a major developer in this space. It received regulatory approval for its autism decision support tool in 2022. Meanwhile, in Japan, new research utilised eye-tracking technology to demonstrate how predictable movement stimuli can be potentially used as a behavioural marker for autism .

100 项与 Ewha Womans University 相关的药物交易

登录后查看更多信息

100 项与 Ewha Womans University 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2026年01月08日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Isuzinaxib ( NOX )	糖尿病肾病更多	临床1期
Drupanol ( DNA-directed DNA polymerase x HIF-1α x NF-κB )	鲍氏不动杆菌感染更多	临床前
Compound 6(Ewha Womans University) ( AMPK )	糖尿病更多	临床前
TG2-179-1 ( BAP1 )	结肠癌更多	临床前
Protocatechualdehyde ( Akt x SOX2 )	乳腺癌更多	临床前